Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2018 Oct;9(5):871-879.
doi: 10.1002/jcsm.12331. Epub 2018 Jul 27.

LY2495655, an Antimyostatin Antibody, in Pancreatic Cancer: A Randomized, Phase 2 Trial

Free PMC article
Clinical Trial

LY2495655, an Antimyostatin Antibody, in Pancreatic Cancer: A Randomized, Phase 2 Trial

Talia Golan et al. J Cachexia Sarcopenia Muscle. .
Free PMC article


Background: Cachexia is a formidable clinical challenge in pancreatic cancer. We assessed LY2495655 (antimyostatin antibody) plus standard-of-care chemotherapy in pancreatic cancer using cachexia status as a stratifier.

Methods: In this randomized, phase 2 trial, patients with stage II-IV pancreatic cancer were randomized to 300 mg LY2495655, 100 mg LY2495655, or placebo, plus physician-choice chemotherapy from a prespecified list of standard-of-care regimens for first and later lines of care. Investigational treatment was continued during second-line treatment. The primary endpoint was overall survival.

Results: Overall, 125 patients were randomized. In August 2014, 300 mg LY2495655 was terminated due to imbalance in death rates between the treatment arms; in January 2015, 100 mg LY2495655 treatment was terminated due to futility. LY2495655 did not improve overall survival: the hazard ratio was 1.70 (90% confidence interval, 1.1-2.7) for 300 mg vs. placebo and 1.3 (0.82-2.1) for 100 mg vs. placebo (recommended doses). Progression-free survival results were consistent with the overall survival results. A numerically higher hazard ratio was observed in patients with weight loss (WL) of ≥5% (cachexia) than with <5% WL within 6 months before randomization. Subgroup analyses for patients stratified by WL in the 6 months preceding enrollment suggested that functional responses to LY2495655 (either dose) may have been superior in patients with <5% WL vs. patients with ≥5% WL. Among possibly drug-related adverse events, fatigue, diarrhoea, and anorexia were more common in LY2495655-treated than in placebo-treated patients.

Conclusions: In the intention-to-treat analysis, LY2495655 did not confer clinical benefit in pancreatic cancer. Our data highlight the importance of assessing survival when investigating therapeutic management of cachexia and support the use of WL as a stratifier (independent of performance status).

Keywords: Cachexia; Muscle mass; Myostatin; Pancreatic cancer.


Figure 1
Figure 1
Patient flow diagram.
Figure 2
Figure 2
Overall survival (A) and progression‐free survival (B) by study arm.

Similar articles

See all similar articles

Cited by 11 articles

See all "Cited by" articles


    1. Society AC . Cancer Facts & Figures 2016. Atlanta: American Cancer Society; 2016.
    1. Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol 2011;12:489–495. - PubMed
    1. Muscaritoli M, Anker SD, Argiles J, Aversa Z, Bauer JM, Biolo G, et al. Consensus definition of sarcopenia, cachexia and pre‐cachexia: joint document elaborated by Special Interest Groups (SIG) "cachexia‐anorexia in chronic wasting diseases" and "nutrition in geriatrics". Clin Nutr 2010;29:154–159. - PubMed
    1. Mueller TC, Burmeister MA, Bachmann J, Martignoni ME. Cachexia and pancreatic cancer: are there treatment options? World J Gastroenterol 2014;20:9361–9373. - PMC - PubMed
    1. Fearon K, Arends J, Baracos V. Understanding the mechanisms and treatment options in cancer cachexia. Nat Rev Clin Oncol 2013;10:90–99. - PubMed

Publication types

MeSH terms